# DBV Technologies S.A. American (DBVT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $13.47, market value $847 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). DBV Technologies S.A. American reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 170.3×**. Each dollar of revenue is priced at 170.3×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 5.0×**. The shares trade at 5.0× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -20.2%** (5-yr avg -34.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -87.1%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 564.5%**. Return on all capital, debt included, is 564.5%: comfortably above what that capital costs.
- **Return on assets: -75.3%**. Each dollar of assets produces -75.3% of profit.

## Growth
- **Revenue growth (1 yr): 35.8%** (3-yr 5.2%/yr, 5-yr -13.0%/yr). Revenue grew 35.8% over the last year, against -13.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 10.3%**. Earnings per share rose 10.3%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Current ratio: 3.67** (quick 3.67). Current assets cover the next year's liabilities 3.67 times.
- **Altman Z-score: 7.58**. A Z-score of 7.58 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. DBV Technologies S.A. American does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 46.1%** (YTD -29.7%, 3-mo -18.8%). The shares are up 46.1% over twelve months including dividends.
- **From 52-week high: -48.6%** (53.2% above the low). Trading 49% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 42**. An RSI of 42 is neutral.
- **Beta (1 yr): 1.02** (volatility 75%). Beta of 1.02 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DBVT · Page: https://foliofundamentals.com/stocks/dbvt

Not investment advice.